| Previous close | 4.500 |
| Open | 4.480 |
| Bid | 4.270 x N/A |
| Ask | 4.280 x N/A |
| Day's range | 4.170 - 4.540 |
| 52-week range | 4.170 - 59.000 |
| Volume | |
| Avg. volume | 3,528,312 |
| Market cap | 375.093M |
| Beta (5Y monthly) | -0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -8.040 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 72.15 |
PR NewswireSirnaomics Demonstrates Strong Antitumor Activity of Its Novel Oligonucleotide-ChemoDrug Conjugate in Journal of Oncology Research and Therapy
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company in discovery and development of RNAi therapeutics, today announced that the Group has published a major advancement of its novel Oligonucleotide-Chemodrug Conjugate (ODC) agent. The ODC demonstrated potent antitumor activity in multiple tumor cell lines and a pancreatic tumor model in mice. The work was published in the latest issue of Journal of Onc
PR NewswireSirnaomics Announces 2023 Annual Results
Sirnaomics Ltd. (the "Company"; together with its subsidiaries, "Sirnaomics" or the "Group"; stock code: 2257), a leading biopharmaceutical company engaged in the discovery and development of advanced RNAi therapeutics, has announced its audited annual results for the year ended 31 December 2023 (the "Year").
PR NewswireSirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference
Sirnaomics Ltd. (the "Company"; stock code: 2257, together with its subsidiaries, the "Group" or "Sirnaomics"), a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, will present its preclinical and clinical development of its GalAhead™ technology-based programs, focusing on an innovative dual-targeted-GalNAc design, muRNA platform drug candidates, at the upcoming 2024 OPT (Oligonucleotide & mRNA Therapeutics) Congress, which took place in Bosto
